Posts

Posted on

Fidelis Insurance Group Schedules First Quarter 2025 Financial Results Conference Call

Fidelis Insurance Group Schedules First Quarter 2025 Financial Results Conference Call

PEMBROKE, Bermuda–(BUSINESS WIRE)–
Fidelis Insurance Holdings Limited (NYSE:FIHL) (“Fidelis Insurance Group” or the “Company”), a global specialty insurer, announced today that it expects to release financial results for the first quarter ended March 31, 2025, on May 14, 2025, after the close of the financial markets. These documents will be available via the Investors section of the Company’s website at https://investors.fidelisinsurance.com.

Dan Burrows, Group Chief Executive Officer, Allan Decleir, Group Chief Financial Officer, and Jonny Strickle, Group Managing Director, will host an investor teleconference, including a question-and-answer period, on May 15, 2025, at 9:00 a.m. ET to discuss the first quarter results as well as related matters.

The teleconference can be accessed by dialing 1-646-564-2877 (U.S. callers), or 1-800-549-8228 (international callers), and entering the passcode 50436 approximately 10 minutes in advance of the call. A live, listen-only webcast of the call will also be available via the Investors section of the Company’s website at https://investors.fidelisinsurance.com.

About Fidelis Insurance Group

Fidelis Insurance Group is a global specialty insurer, leveraging strategic partnerships to offer innovative and tailored insurance solutions.

We have a highly diversified portfolio that we believe allows us to take advantage of the opportunities presented by evolving (re)insurance markets, proactively shift our business mix across market cycles, and produce superior underwriting returns.

Headquartered in Bermuda, with offices in Ireland and the United Kingdom, Fidelis Insurance Group operating companies have an insurer financial strength rating of A from AM Best, A- from S&P and A3 from Moody’s. For additional information about Fidelis Insurance Group, our people, and our products please visit our website at www.FidelisInsurance.com.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release, in interviews and in related posts, constitute “forward-looking statements,” and are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause Fidelis’ actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to rely on forward-looking statements, and, except as required by law, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, Fidelis assumes no obligation and does not intend to update or revise these forward-looking statements after the date of this press release, whether as a result of new information, future events, or otherwise.

Fidelis Insurance Group Investor Contact:

Fidelis Insurance Group

Miranda Hunter

+1 441 279 2561

[email protected]

Fidelis Insurance Group Media Contact:

Rein4ce

Sarah Hills

+44 (0)7718 882011

[email protected]

KEYWORDS: Caribbean United States Bermuda North America

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Posted on

Stellantis to Announce First Quarter 2025 Shipments and Revenues on April 30

Stellantis to Announce First Quarter 2025

Shipments and Revenues on April 30

AMSTERDAM, April 17, 2025 – Stellantis N.V. announced today that its First Quarter 2025 Shipments and Revenues will be released on Wednesday, April 30, 2025.

A live audio webcast and conference call for the First Quarter 2025 Shipments and Revenues will begin at 1:00 p.m. CEST / 7:00 a.m. EDT on Wednesday, April 30, 2025.

The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website (www.stellantis.com) at approximately 8:00 a.m. CEST / 2:00 a.m. EDT on April 30, 2025.

Details for accessing this presentation are available under the Investors section of the corporate website. For those unable to participate in the live session, a recorded replay will be accessible following the event.

# # #


About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep

®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit

www.stellantis.com

.

@Stellantis Stellantis Stellantis Stellantis

For more information, contact:

Fernão SILVEIRA   +31 6 43 25 43 41 – [email protected]

Nathalie ROUSSEL   +33 6 87 77 41 82 – [email protected]

[email protected]
www.stellantis.com

Attachment



Posted on

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: The AZEK Company Inc. (NYSE – AZEK), Mesa Air Group, Inc. (Nasdaq – MESA), Mr. Cooper Group Inc. (Nasdaq – COOP), Optinose, Inc. (Nasdaq – OPTN)

BALA CYNWYD, Pa., April 17, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Mr. Cooper Group Inc. (Nasdaq – COOP)

Under the terms of the Merger Agreement, Mr. Cooper will be acquired by Rocket Companies in an all-stock transaction for $9.4 billion in equity value. Mr. Cooper shareholders will receive a fixed exchange ratio of 11.0 Rocket shares for each share of Mr. Cooper common stock, representing $143.33 per share value based on the closing price as of March 28, 2025. (NYSE – RKT) The investigation concerns whether the Mr. Cooper Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/mr-cooper-group-inc-nasdaq-coop/.

The AZEK Company Inc. (NYSE – AZEK)

Under the terms of the agreement, AZEK will be acquired by James Hardie Industries plc (NYSE – JHX) (“James Hardie”). AZEK shareholders will receive $26.45 in cash and 1.0340 ordinary shares of James Hardie to be listed on the New York Stock Exchange (NYSE) for each share of AZEK common stock they own. The stock and cash consideration represents a total per share value of $56.88. The investigation concerns whether the AZEK Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

Additional information can be found at https://www.brodskysmith.com/cases/azek-company-inc-nyse-azek/.

Optinose, Inc. (Nasdaq – OPTN)

Under the terms of the Merger Agreement, Optinose will be acquired by Paratek Pharmaceuticals for $9.00 per share in cash, plus up to $5.00 per share in CVRs payable in the event that certain net revenue milestones are achieved. The investigation concerns whether the Optinose Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

Additional information can be found at https://www.brodskysmith.com/cases/optinose-inc-nasdaq-optn/.

Mesa Air Group, Inc. (Nasdaq – MESA)

Under the terms of the agreement, Mesa will be acquired by Republic Airways Holdings Inc.(“Republic”). On the close of the all-stock transaction, Republic shareholders will own 88% of the combined company’s common shares. Mesa shareholders will own a minimum of 6%, and up to 12% of the combined company dependent upon Mesa’s achievement of certain pre-closing criteria. The investigation concerns whether the Mesa Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined Company.

Additional information can be found at https://www.brodskysmith.com/cases/mesa-air-group-inc-nasdaq-mesa/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.



Posted on

Stagwell (STGW) Schedules Webcast to Discuss Financial Results for the Three Months Ended March 31, 2025

PR Newswire


NEW YORK
, April 17, 2025 /PRNewswire/ — Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, will report financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, before market open.

Stagwell will host a video webcast to review those results the same day at 8:30 AM (ET). Register here to attend the webcast.

A replay of the webcast will be available following the event at Stagwell’s website, https://www.stagwellglobal.com/investors/.

About Stagwell

Stagwell is the challenger holding company built to transform marketing. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 40+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com. 

Contacts

For Investors:

Ben Allanson

[email protected]

For Press:

Kara Gelber

[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stagwell-stgw-schedules-webcast-to-discuss-financial-results-for-the-three-months-ended-march-31-2025-302430873.html

SOURCE Stagwell Inc.

Posted on

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene – Expands Global IP in Precision Oncology Platform

PR Newswire


Patent Grant Strengthens Hoth’s RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications


NEW YORK
, April 17, 2025 /PRNewswire/ — Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics.

The newly issued patent secures broad claims covering antisense oligomers that target the KIT gene — a clinically validated oncogene associated with gastrointestinal stromal tumors (GIST), leukemia, mastocytosis, and other cancers. These oligomers are designed to alter pre-mRNA splicing or reduce KIT protein expression, offering a highly targeted therapeutic mechanism.

“This patent significantly strengthens Hoth’s position in the RNA therapeutics space and marks a major milestone in our global strategy,” said Robb Knie, CEO of Hoth Therapeutics. “Targeting the KIT pathway with antisense technology represents a precision-driven approach that holds immense potential in oncology and beyond. This grant provides strong validation and global momentum as we continue advancing our RNA platform toward the clinic.”

The patent includes coverage for:

  • Antisense RNA molecules comprising 10–50 nucleotides targeting KIT pre-mRNA splicing sequences
  • Morpholino and chemically modified antisense variants
  • Pharmaceutical compositions and expression vectors
  • Applications in both human and veterinary medicine

Why It Matters:
The KIT gene is implicated in aggressive and difficult-to-treat cancers. By leveraging antisense oligonucleotides (ASOs) to modulate KIT expression, Hoth is pioneering a novel RNA-based strategy that could bypass traditional small molecule resistance mechanisms. With this patent, Hoth now holds exclusive rights to develop, partner, and commercialize ASO-based therapies targeting KIT — a critical asset in the precision oncology space.

Key Highlights:

  • Patent grant accelerates Hoth’s global IP expansion in RNA-targeted therapies
  • Targets validated oncogene KIT, widely implicated in cancer progression and resistance
  • Supports pipeline momentum in oncology, immunology, and rare diseases
  • Creates licensing and partnership opportunities in high-growth therapeutic areas

About Hoth Therapeutics, Inc.

 Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth’s current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of any health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms, or the negative of those terms. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC 
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-granted-japanese-patent-for-novel-rna-based-cancer-therapy-targeting-kit-gene–expands-global-ip-in-precision-oncology-platform-302431170.html

SOURCE Hoth Therapeutics, Inc.

Posted on

Skyworks Sets Date for Second Quarter Fiscal 2025 Earnings Release and Conference Call

Skyworks Sets Date for Second Quarter Fiscal 2025 Earnings Release and Conference Call

May 7 at 4:30 p.m. EDT

IRVINE, Calif.–(BUSINESS WIRE)–
Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, will host a conference call with analysts to discuss its second quarter fiscal 2025 results and business outlook on May 7, 2025, at 4:30 p.m. EDT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417840155/en/

Skyworks Sets Date for Second Quarter Fiscal 2025 Earnings Release and Conference Call May 7 at 4:30 p.m. EDT

Skyworks Sets Date for Second Quarter Fiscal 2025 Earnings Release and Conference Call May 7 at 4:30 p.m. EDT

After the close of the market on May 7, and prior to the conference call, Skyworks will issue a copy of the earnings press release via Business Wire. The press release may also be viewed on Skyworks’ website at www.skyworksinc.com/investors.

To listen to the conference call, please visit the investor relations section of Skyworks’ website at https://investors.skyworksinc.com/events-presentations. Playback of the conference call will be available on Skyworks’ website at www.skyworksinc.com/investors beginning at 9 p.m. EDT on May 7, 2025. Additionally, a transcript of the company’s prepared remarks will be made available on our website promptly after their conclusion during the call.

About Skyworks

Skyworks Solutions, Inc. is empowering the wireless networking revolution. Our highly innovative analog and mixed-signal semiconductors are connecting people, places and things spanning a number of new and previously unimagined applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables.

Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit Skyworks’ website at: www.skyworksinc.com.

Safe Harbor Statement

Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties, including those identified in the “Risk Factors” section of Skyworks’ most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks’ SEC filings can be obtained, free of charge, on Skyworks’ website (www.skyworksinc.com) or at the SEC’s website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:

Constance Griffiths

(949) 230-4867

[email protected]

Investor Relations:

Raji Gill

(949) 508-0973

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Semiconductor Hardware Mobile/Wireless Technology

MEDIA:

Photo
Photo
Skyworks Sets Date for Second Quarter Fiscal 2025 Earnings Release and Conference Call May 7 at 4:30 p.m. EDT
Logo
Logo
Posted on

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025.

To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company’s website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:

Caitlin Lowie
[email protected]



Posted on

NXP Semiconductors Announces Conference Call to Review First Quarter 2025 Financial Results

EINDHOVEN, The Netherlands, April 17, 2025 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today announced it will release financial results for the first quarter 2025 after the close of normal trading on the NASDAQ Global Select Market on Monday, April 28, 2025. The company will host a conference call with the financial community on Tuesday, April 29, 2025, at 8:00 a.m. U.S. Eastern Daylight Time (EDT).

Earnings Conference Call Details 
Interested parties may pre-register for the webcast or obtain a user-specific access code to join the live conference call.

A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About NXP Semiconductors 

NXP Semiconductors N.V. (NASDAQ: NXPI) is the trusted partner for innovative solutions in the automotive, industrial & IoT, mobile, and communications infrastructure markets. NXP’s “Brighter Together” approach combines leading-edge technology with pioneering people to develop system solutions that make the connected world better, safer, and more secure. The company has operations in more than 30 countries and posted revenue of $12.61 billion in 2024. Find out more at www.nxp.com.

   
For further information, please contact:  
   
Investor: Media:
Jeff Palmer Paige Iven
[email protected] [email protected]
+1 408 205 0687 +1 817 975 0602
   

NXP-CORP 



Posted on

Costamare Inc. Announces Plans for Costamare Bulkers Holdings Limited Spin-Off

  • Record date set for April 29, 2025
  • Distribution date for Costamare Bulkers shares anticipated to be May 6, 2025

MONACO, April 17, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) today announced that its Board of Directors has approved the previously announced spin-off of its dry bulk business into a standalone company, Costamare Bulkers Holdings Limited (“Costamare Bulkers”). The Company expects to complete the transaction, by way of a pro rata distribution to Costamare Inc. shareholders, on May 6, 2025.

Additional information regarding Costamare Bulkers and the proposed spin-off transaction may be found in the Registration Statement on Form 20-F (the “Registration Statement”) filed by Costamare Bulkers with the U.S. Securities and Exchange Commission (the “SEC”), which is available at www.sec.gov.

Timeline for planned spin-off

Date Event
April 29, 2025 Record date
“Due-bill” trading of Costamare Inc. shares begins
May 1, 2025 “When-issued” trading of Costamare Bulkers shares begins
“Ex-distribution” trading of Costamare Inc. shares begins
May 6, 2025 Last day of “due-bill”, “when-issued” and “ex-distribution” trading
Distribution of Costamare Bulkers shares to holders of Costamare Inc. shares
May 7, 2025 Regular-way trading of Costamare Bulkers shares begins
   
  • Record date: To accomplish the spin-off, Costamare Inc. will distribute all of the Costamare Bulkers shares held by Costamare Inc. to holders of Costamare Inc. common shares on a pro rata basis. In the distribution, each Costamare Inc. shareholder will receive one common share of Costamare Bulkers share for every five Costamare Inc. common shares they hold as of the close of business on April 29, 2025, the record date for the distribution.
  • “Due-bill” trading: The New York Stock Exchange (the “NYSE”) will implement a “due-bill” trading market for Costamare Inc. shares beginning on April 29, 2025 and continuing through the Distribution Date (defined below), meaning that Costamare Inc. shares will trade with an entitlement to shares of Costamare Bulkers to be distributed pursuant to the distribution.
  • “When-issued” and “ex-distribution” trading: Beginning on or about May 1, 2025 and continuing through the Distribution Date, it is expected that Costamare Bulkers shares will trade on a “when-issued” basis on the NYSE under the ticker symbol “CMDB WI.”

    Also beginning on or about May 1, 2025 and continuing through the Distribution Date, it is expected that there will be two markets in Costamare Inc. common shares. Costamare Inc. shares that trade in the “regular-way” market under the symbol “CMRE” will trade with an entitlement to shares of Costamare Bulkers to be distributed pursuant to the distribution. Costamare Inc. shares that trade in the “ex-distribution” market under the symbol “CMRE WI” will trade without an entitlement to Costamare Bulkers shares. Costamare Inc. shareholders who sell their shares in the “regular-way” market from the record date and up to and including the Distribution Date will also be selling their entitlement to receive Costamare Bulkers shares in the distribution. Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling Costamare Inc. shares on or before the Distribution Date.

  • Distribution date: Holders of Costamare Inc. common shares will receive one common share of Costamare Bulkers for every five Costamare Inc. common shares held as of the record date. Costamare Inc. shareholders will receive cash upon the sale of the aggregated fractional shares in lieu of any fractional shares. The distribution is expected to occur at 5:00 p.m., New York City time, on May 6, 2025 (the “Distribution Date”), subject to customary conditions. At market close on May 6, 2025, when-issued trading of Costamare Bulkers’ shares and ex-distribution trading of Costamare Inc.’s shares will end.
  • Listing date: On May 7, 2025, Costamare Bulkers shares are expected to be listed and traded “regular-way” on the NYSE under the ticker symbol “CMDB.” Costamare Inc. will continue to trade on the NYSE under the ticker symbol “CMRE.”

The proposed distribution and spin-off remain subject to, among other things, the Registration Statement being declared effective by the SEC and the approval of the listing of the Costamare Bulkers common shares on the NYSE.

Morgan Stanley & Co. LLC is advising Costamare Inc. on the transaction.

About Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Limited will be an international owner and operator of dry bulk vessels. Costamare Bulkers’ owned dry bulk fleet will consist of 38 vessels with a total carrying capacity of approximately 3,017,000 dwt, including one vessel that Costamare Bulkers has agreed to sell, with a carrying capacity of approximately 76,600 dwt. Costamare Bulkers will also own a dry bulk operating platform (CBI) which charters in/out dry bulk vessels, enters into contracts of affreightment, forward freight agreements and may also utilize hedging solutions. Costamare Bulkers’ common stock will trade on the New York Stock Exchange under the symbol “CMDB”.

About Costamare Inc.

Costamare Inc. is one of the world’s leading owners and providers of containerships for charter. The Company has 51 years of history in the international shipping industry and a fleet of 68 owned containerships, with a total capacity of approximately 513,000 TEU. The Company also participates in a leasing business. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C” and “CMRE PR D”, respectively.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could” and “expect” and similar expressions, or by express or implied discussions regarding the potential completion of the announced spin-off of Costamare Bulkers, regarding whether the announced spin-off is in the best interests of shareholders, regarding the future commercial performance of Costamare Inc. or Costamare Bulkers, or regarding any potential strategic benefits, synergies or opportunities as a result of these actions. You should not place undue reliance on these statements. These statements are not historical facts but instead represent only the Company’s beliefs regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. There can be no guarantee that the proposed transaction will be completed in the expected form or within the expected time frame or at all. Nor can there be any guarantee that Costamare Inc. or a separate dry bulk business will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of these actions, that shareholders will achieve any particular level of shareholder returns or that the spin-off of Costamare Bulkers will be in the best interests of shareholders. For a discussion of some of the risks and important factors that could affect future results, see the discussions in the Company’s Annual Report on Form 20-F (File No. 001-34934) and Costamare Bulkers’ Registration Statement on Form 20-F (File No. 001-42581).

This press release is not an offer to sell, or a solicitation of an offer to buy or sell, any securities of Costamare Inc. or Costamare Bulkers, and may not be relied upon in connection with the purchase or sale of any such security. Should you wish to invest in Costamare Bulkers, you should do so solely on the basis of information filed by Costamare Bulkers with the SEC at or around the time of the spin-off, including the section “Risk Factors” included in the Registration Statement that Costamare Bulkers has filed with the SEC. The information filed with the SEC will be available on the SEC’s website at www.sec.gov.

Company Contacts:

Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: [email protected]



Posted on

Uniti Nominates Harold Zeitz for Election to its Board of Directors

Jennifer Banner Recognized for Her 10 Years of Dedicated Service

LITTLE ROCK, Ark., April 17, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced that its Board of Directors (the “Board”) has nominated Harold Zeitz for election to the Board as an independent director at the 2025 annual meeting of stockholders (the “Annual Meeting”). The Board also nominated current directors, Francis X. “Skip” Frantz (Chairman of the Board), Scott Bruce, Carmen Perez-Carlton, and Kenny Gunderman (President and CEO of Uniti) for re-election to the Board. The Company also announced that Jennifer Banner will not stand for re-election, and her current term as a director will end at the Annual Meeting following a decade of service. The Board acknowledges with gratitude Ms. Banner’s service on the Board and her contributions to Uniti and its management team.

Zeitz currently serves as CEO of Ziply Fiber, the leading fiber internet provider in the Pacific Northwest. He will bring to the Board over 30 years of experience in leading companies that deliver superior experiences to customers in the broadband, telecom, wireless, financial services, gaming and web services industries.

“We are delighted to announce the nomination of Harold to the Uniti Board at this exciting time for our company,” said Mr. Frantz, Chairman of the Board. “Harold is a highly respected leader with deep expertise in our industry. His strategic insights and experience will be invaluable as we continue to execute our strategy to create a national fiber powerhouse and drive long-term growth and value creation.”

“I am delighted to have the opportunity to join Uniti’s Board,” said Zeitz. “Uniti is at an exciting point in its journey, and I am looking forward to working with the Board and the management team to help drive its strategic goals forward, fulfill its enormous potential, and create long-term value for Uniti’s shareholders.”

“We are very grateful for Jenny’s impactful and lasting service to Uniti,” added Frantz. “We have benefited greatly from her thoughtful counsel and leadership over the past ten years.”

ABOUT HAROLD ZEITZ

Harold Zeitz serves as Chief Executive Officer of Ziply Fiber. Prior to joining Ziply Fiber, Mr. Zeitz served as President and COO of Wave Broadband, a leading broadband data company in WA, OR and CA. He also served in executive and leadership roles at Classmates, IGT, RealNetworks, Sharebuilder, AT&T Wireless and McCaw Cellular. Mr. Zeitz holds a BA in Economics from Northwestern University and an MBA from the Stanford Graduate School of Business. He is a Board Trustee at Horizon House and a Board Member of Race Communications.

ABOUT UNITI

Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of fiber and other wireless solutions for the communications industry. As of December 31, 2024, Uniti owns approximately 145,000 fiber route miles, 8.8 million fiber strand miles, and other communications real estate throughout the United States. Additional information about Uniti can be found on its website at www.uniti.com.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

The Company intends to file a proxy statement and proxy card (the “2025 Proxy Statement”) with the SEC in connection with the solicitation of proxies for the Annual Meeting. This communication is not intended to be, and is not, a substitute for the 2025 Proxy Statement or any other document that the Company may file with the SEC in connection with the Annual Meeting. The 2025 Proxy Statement will contain important information about the Company, the Annual Meeting, and related matters.

BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE 2025 PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by the Company with the SEC, are available for no charge at the SEC’s website at www.sec.gov and at the Company’s investor relations website at https://investor.uniti.com/financial-information/sec-filings.

PARTICIPANTS IN THE SOLICITATION

The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the Annual Meeting. Information regarding the names of the Company’s directors and executive officers and their respective interests in the Company by security holdings or otherwise is set forth in the Company’s proxy statement for the 2024 Annual Meeting of stockholders, filed with the SEC on April 11, 2024 (the “2024 Proxy Statement”) and will be set forth in the 2025 Proxy Statement and accompanying solicitation materials. To the extent holdings of such participants in the Company’s securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Statements of Change in Ownership on Form 4 filed with the SEC (these documents may be obtained as indicated above).

INVESTOR AND MEDIA CONTACTS:

Paul Bullington, 251-662-1512
Senior Vice President, Chief Financial Officer & Treasurer
[email protected]

Bill DiTullio, 501-850-0872
Senior Vice President, Investor Relations & Treasury
[email protected]

This press release was published by a CLEAR® Verified individual.